Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
SAN DIEGO, Nov. 14, 2016 -- TearLab Corporation (NASDAQ:TEAR) (TSX: TLB) (the “Company”) announced today that Wes Brazell, CFO, is scheduled to present at the 7th Annual Craig-Hallum Alpha Select Conference on November 16, 2016 at the Sheraton New York Times Square Hotel in New York.
Event: 7th Annual Craig-Hallum Alpha Select Conference
Date: Wednesday, November 16, 2016
Time: 9:20 am EST
Location: Sheraton New York Times Square Hotel – New York City
The presentation will be webcast live and available for replay in the Investors section of TearLab’s website at http://www.tearlab.com/investors/webcasts.htm or on the Craig-Hallum website at http://wsw.com/webcast/ch6/tear.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others, statements concerning our future financial and operational performance including anticipated savings from the strategic restructuring, opportunities associated with new program offerings, accessing future capital, plans with respect to our marketing strategy, and potential results of our new co-promotion agreement with PRN. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2015, filed with the SEC on March 9, 2016, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the SEC on November 9, 2016. We do not undertake to update any forward-looking statements except as required by law.
CONTACT: Investor Contact: The Ruth Group David Burke Tel: 646-536-7009 [email protected]
